PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators

Size: px
Start display at page:

Download "PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators"

Transcription

1 Polish-Italian-Hungarian Randomized ThrombEctomy Trial PIHRATE Trial On behalf PIHRATE investigators Dariusz Dudek MD, PhD Institute of Cardiology, Krakow, Poland

2 Impact of distal embolization Distal embolization occurs in 15% patients after PCI Henriques et al. EHJ 2002;23:1112-7

3 Aim: Primary percutaneous coronary intervention efficacy improvement by DIVER CE thrombectomy system leading to thrombus reduction. Study design: Multicenter, prospective, non-blinded, randomized. Primary endpoint: ST resolution >70% 60 minutes after PCI.

4 Secondary endpoints Thrombectomy system efficacy: passing trough lesion with thrombus reduction followed by direct stenting ctfc: corrected TIMI frame count MBG 3: myocardial blush grade STR>70% immediately after PCI Rate of composite angiographic adverse events including: distal embolisation, transient no-reflow or slow flow, final TIMI <3, need of bail out GpIIb/IIIa inhibitors or adenosine or nitroprosside Major adverse cardiac events (MACE): cardiac death, remi, repci/cabg CMR: measurement of left ventricular end-diastolic volume and end-systolic volume, ejection fraction, infarct size

5 Study design STEMI <6hr ST elevation >3 mm in one lead TIMI 0 or 1 TIMI. ctfc. MBG RANDOMIZATION Grup I THROMBECTOMY Grup II PREDILATATION TIMI 0 or 1 POBA STENTING TIMI. ctfc. MBG TIMI 2 or 3 DIRECT STENTING TIMI. ctfc. MBG TIMI. ctfc. MBG STENT IMPLANTATION TIMI. ctfc. MBG ST SEGMENT RESOLUTION 60 MINUTES AFTER PCI CK/CK-MB LEAK: every 6 hours for 24 hours CMR in the subgroup of patients EDV. ESV. mass and ejection fraction. delayed-contrast-enhancement 6 months follow up MACE: 30 day and 6 month follow up

6 Sample size calculation For primary endpoint assuming that patients from thrombectomy group will achieve >70% ST segment resolution 60 minutes after PCI in 65% and patient from control group achieve in 40%. For 80% test power and statistical significance level 0.05 to demonstrate such difference 70 patients in every group is needed. Due to some ECG which will not fulfill analysis criteria and to strength findings study groups will be enlarged to 100 patients per group.

7 PI: Dariusz Dudek Zabrze Silesian Center of Cardiology Gasior 33 Krakow University Hospital Mielecki 31 Rome Institute of Cardiology Burzotta 22 Nowy Sacz Cardiology Department Legutko 22 Warszawa Institute of Cardiology Witkowski 20 Genua Hospital Villascasi Rubartelli 17 Krakow John Paul II Hospital Zmudka 14 Przemysl Community Hospital Wisniewski 14 Katowice Silesian School of Medicine Ochala 13 Pecs Heart Institute Horvath 10

8 Study organization Study Coordination Angiographic CoreLaboratory ECG CoreLaboratory Krakow Cardiovacular Research Institute, Krakow, Poland. Krakow Cardiovacular Research Institute, Krakow, Poland. Silesian Center of Cardiology, Zabrze, Poland. NCT

9 Baseline characteristic Thrombectomy Predilatation p n Age 61 ± ± Male 79 % 81 % 0.7 CAD history 13 % 4 % 0.04 Previous infarction 2 % 0 % 0.17 Hypertension 58 % 54% 0.56 Smoking 63 % 63 % 0.9 Diabetes 12 % 10 % 0.5 Hyperlipidemia 42% 50 % 0.33 Family hist of CAD 33 % 26 % 0.28 Killip 1 Killip 2 Killip 3 Killip 4 83 % 15 % 2 % 0% 91 % 8 % 1 % 0% BP systolic 132 ± ± BP diastolic 81 ± ± HR 78 ± ±

10 Angiographic baseline characteristics 50,1% 10,7% Thrombectomy 38,2% IRA LAD Cx RCA p= ,2% Predilatation 12,9% 40,9% 30% 25% Small Thrombus Large Thrombus ~30% ~70% p=0.76 Thrombectomy Predilatation 20% 15% 10% TIMI Thrombus scale after wiring 5% 0%

11 Technical aspects Thrombectomy Predilatation p Stent implantation, % Direct stenting, % 75 5 < Stent diameter, mm 3.3 ± ± Stent length, mm 19.4 ± ± Max pressure, atm 14.8 ± ± Abciximab, %

12 DIVER CE Efficacy Successful thrombectomy & direct stenting 75% no lesion passing 2% no thrombus removal 7% no direct stenting 16%

13 Angiographic results Thrombectomy Predilatation p TIMI 3 baseline 0 % 2 % 0.07 TIMI 3 after thrombectomy/predilatation 54 % 63 % 0.33 TIMI 3 final 88 % 82 % 0.4 Thrombectomy Predilatation p ctfc baseline 99 ± 8 98 ± ctfc after thrombectomy/predilatation 44 ± ± ctfc final 28 ± ±

14 Primary Endpoint STR > 70% (60 minutes after PCI) 60% p= % 40% 30% 50% 41% Thrombectomy Predilatation 20% 10% 0%

15 Primary Endpoint STR > 70% (immediately after PCI) 60% 50% 40% 30% 20% 10% 0% 41% p= % Thrombectomy Predilatation

16 Secondary Endpoints Thrombectomy Predilatation STR 70% (immediately after PCI) 41% 27% MBG 3 76% 59% MBG 3 + TIMI 3 73% 56% 0.02 MBG 3 + STR 70% (immediately after PCI) 35% 12% MBG3 + STR>70% (60 min after PCI) 39% 24% MBG 3 + TIMI 3 +STR 70% (immediately after PCI) MBG 3 + TIMI 3 + STR>70% (60 min after PCI) 35% 12% % 22% 0.07

17 Periprocedural complications Thrombectomy Predilatation p Periprocedural complication 15.7% 22.6% 0.22 Distal embolisation 4.9% 5.4% 0.88 No-Flow / Slow-flow 9.8% 16.1% 0.18 Bail out IIb/IIIa 8% 10.5% 0.54 Adenosine / nitropruside 2.9% 8.6% 0.08

18 Six Month Follow Up 7% p=0.74 p=0.29 p=0.7 6,2% 6% 5% 5,0% 4% 3% 4,0% 3,1% 3,1% Thrombectomy Predilatation 2% 1% 1,0% 0% Death ReMI Death+ReMI

19 Conclusions In patients with STEMI with occluded infarct related artery simple thrombectomy and direct stenting provides better myocardial reperfusion than standard balloon predilatation followed by stent implantation. Aspiration thrombectomy and direct stenting is easy. safe and effective in STEMI patient with early presentation.

20 CAN WE HAVE A FLOW-CHART FOR THROMBUS-ASPIRATION USE? STEMI PT ARRIVES TO CATH LAB TIMI 0-1 GUIDEWIRE CROSSING OF CULPRIT LESION TIMI 2-3 See Flow See Thrombus Burden THROMBECTOMY SMALL THROMBUS-BURDEN LARGE THROMBUS-BURDEN TIMI 2-3 DIRECT STENTING SMALL-MID VESSEL LARGE VESSEL See culprit vessel NoTIMI 2-3 Small Balloon Predilatation THROMBECTOMY CONSIDER DISTAL PROTECTION or/and THROMBECTOMY with fragmentation (Spectranetics. AngioJet)?

21 Authors Dariusz Dudek Waldemar Mielecki Francesco Burzotta Mariusz Gasior Adam Witkowski Andrzej Ochala Paolo Rubartelli Ivan Horvath Roman M. Wojdyla Michal Hawranek Piotr Buchta Jerzy Pregowski Daniel Aradi Jacek Legutko Krzysztof Zmudka

Reperfusion in STEMI. Pharmacoinvasive therapy The Krakow experience

Reperfusion in STEMI. Pharmacoinvasive therapy The Krakow experience Reperfusion in STEMI Pharmacoinvasive therapy The Krakow experience Dariusz Dudek Jacek Legutko,, Jarosław Zalewski, Krzysztof śmudka Institute of Cardiology Jagiellonian University Medical College Krakow,

More information

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,

More information

THE RISE AND FALL OF ROUTINE MANUAL THROMBECTOMY FOR ST-ELEVATION MYOCARDIAL INFARCTION

THE RISE AND FALL OF ROUTINE MANUAL THROMBECTOMY FOR ST-ELEVATION MYOCARDIAL INFARCTION THE RISE AND FALL OF ROUTINE MANUAL THROMBECTOMY FOR ST-ELEVATION MYOCARDIAL INFARCTION Vincent Floré, *Stephen P Hoole Department of Interventional Cardiology, Papworth Hospital NHS Foundation Trust,

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III Gilles Montalescot, MD, PhD Pitié-Salpêtrière Hospital, Paris, France

More information

OCT STEMI: OCT guidance during stent implantation

OCT STEMI: OCT guidance during stent implantation OCT STEMI: OCT guidance during stent implantation in primary PCI. A Randomized Multicenter study with 9-month optical coherence tomography follow-up Červinka P 1,2, Kala P 3, Jakl M 2,4, Kaňovský J 3,

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

California Health and Safety Code, Section 1256.01

California Health and Safety Code, Section 1256.01 California Health and Safety Code, Section 1256.01 1256.01. (a) The Elective Percutaneous Coronary Intervention (PCI) Pilot Program is hereby established in the department. The purpose of the pilot program

More information

No conflict of interest

No conflict of interest Anthony Fung Presenter Disclosure The BRIEF-PCI Trial No conflict of interest Brief Infusion of Eptifibatide Following PCI The BRIEF-PCI Trial AY Fung, J Saw, A Starovoytov, C Densem, P Jokhi, SJ Walsh,

More information

Gregg W. Stone, MD. Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation

Gregg W. Stone, MD. Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation INFUSE-AMI A 2x2 Factorial, Multicenter, Prospective, Randomized Evaluation of Intracoronary Abciximab and Aspiration Thrombectomy in Patients Undergoing Primary PCI for Anterior STEMI Gregg W. Stone,

More information

Majestic Trial 12 Month Results

Majestic Trial 12 Month Results Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.

More information

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br. The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies Christoph Hehrlein, University Clinic Freiburg i.br. Germany Disclosure Statement of Financial Interest Within the past 12 months,

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Appropriate Use: Big Brother is Watching. Jason H. Rogers, MD Director, Interventional Cardiology UC Davis Medical Center

Appropriate Use: Big Brother is Watching. Jason H. Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Appropriate Use: Big Brother is Watching Jason H. Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Disclosures Consultant Boston Scientific, Medtronic, Middle Peak Medical, Millipede,

More information

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital

More information

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent

More information

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting

More information

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Coronary Bifurcation Treatment: Update from the European Bifurcation Club Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy) Disclosure Statement of Financial Interest Within the past 12 months, I

More information

Prognostic impact of uric acid in patients with stable coronary artery disease

Prognostic impact of uric acid in patients with stable coronary artery disease Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,

More information

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf

More information

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Ostial LAD: Single stent approach is the best Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI Chair, Interventional Cardiology Sanatorio San Lucas Instituto Alexander Fleming Buenos

More information

Antonio Colombo MD on behalf of the SECURITY Investigators

Antonio Colombo MD on behalf of the SECURITY Investigators Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY

More information

Role of elevated heart rate in the development of cardiovascular disease in hypertension

Role of elevated heart rate in the development of cardiovascular disease in hypertension ONLINE SUPPLEMENT Role of elevated heart rate in the development of cardiovascular disease in By Palatini P Department of Clinical and Experimental Medicine University of Padova, Padua, Italy Running title:

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

Abnormal, Autoquant Adenosine Myocardial Perfusion Heart Imaging

Abnormal, Autoquant Adenosine Myocardial Perfusion Heart Imaging Background: Reason: preoperative assessment of CAD, Shortness of Breath Symptom: atypical chest pain Risk factors: hypertension Under influence: a beta blocker Medications: digoxin Height: 66 in. Weight:

More information

FFR CT : Clinical studies

FFR CT : Clinical studies FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity

More information

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data

More information

Pantera Lux Device Description and Overview of Clinical Data

Pantera Lux Device Description and Overview of Clinical Data Pantera Lux Device Description and Overview of Clinical Data Ralph Tölg, MD Herzzentrum Segeberger Kliniken GmbH Bad Segeberg, Germany Disclosure Statement of Financial Interest Within the past 12 months,

More information

BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the

BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI Thirty-Day and One-Year Outcomes of the BRIGHT Trial Yaling Han, MD, FACC On behalf of the BRIGHT investigators

More information

PINC in Krakow 12. 9 th Peripheral Interventions Workshop 31 May - 1 June 2012. Hotel Andel s Krakow

PINC in Krakow 12. 9 th Peripheral Interventions Workshop 31 May - 1 June 2012. Hotel Andel s Krakow Department of Interventional Cardiology Institute of Cardiology, Jagiellonian University University Hospital in Krakow 17, Kopernika St., 31-501 Krakow PINC in Krakow 12 9 th Peripheral Interventions Workshop

More information

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program Jean Fajadet, MD, FESC Clinique Pasteur - Toulouse - France Disclosure statement Nothing to disclose Dedicated Delivery

More information

Antiplatelet and Antithrombotics From clinical trials to guidelines

Antiplatelet and Antithrombotics From clinical trials to guidelines Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories

More information

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

LEADERS: 5-Year Follow-up

LEADERS: 5-Year Follow-up LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS

More information

The Cardiac Society of Australia and New Zealand

The Cardiac Society of Australia and New Zealand The Cardiac Society of Australia and New Zealand Guidelines on Support Facilities for Coronary Angiography and Percutaneous Coronary Intervention (PCI) including Guidelines on the Performance of Procedures

More information

06 Validation of risk prediction model

06 Validation of risk prediction model HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via

More information

Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases

Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases T. Masood,T. Sagheer,D. Jan,N. Qamar,A.M.A. Faruqui ( National Institute of Cardiovascular Diseases (NICVD), Karachi.

More information

Popliteal artery: to stent or not to stent?

Popliteal artery: to stent or not to stent? Popliteal artery: to stent or not to stent? Karl-Ludwig Schulte Vascular Center Berlin Ev. Hospital Königin Elisabeth St. Gertrauden Hospital University Hospital Charité, CC11 Humboldt-University Berlin

More information

HA Territory-wide PCI Audit 2003-05

HA Territory-wide PCI Audit 2003-05 HA Territory-wide PCI Audit 23-5 5 PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 26 Percutaneous Coronary Intervention Background HA AP target 2/3, coordinated by PCI Working

More information

Cardiovascular disease has become a dominant cause of

Cardiovascular disease has become a dominant cause of Abstract Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman Panduranga Prashanth, Mohamed Mukhaini, Abdulla A. Riyami, Kadhim

More information

Thrombolysis, thromboaspiration, ultrasound thrombectomy: adjuncts techniques for aorto-iliac recanalization.

Thrombolysis, thromboaspiration, ultrasound thrombectomy: adjuncts techniques for aorto-iliac recanalization. Thrombolysis, thromboaspiration, ultrasound thrombectomy: adjuncts techniques for aorto-iliac recanalization. Dr. S. Schepers Dr. F. Van Elst Sint-Trudo Hospital Sint-Truiden Belgium Chronic aorto-iliac

More information

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Drug-Eluting Balloons Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam Potential conflicts of interest Speaker s name: Klaus Bonaventura

More information

Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents

Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents Early healing after treatment of coronary lesions by everolimus, or biolimus eluting bioresorbable polymer stents One-month results of the study Ida Riise Balleby 1, Trine Krejberg Ørhøj 1, Christian Juhl

More information

Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up

Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS

More information

Utilizing the Cath Lab for Cardiac Arrest

Utilizing the Cath Lab for Cardiac Arrest Utilizing the Cath Lab for Cardiac Arrest Khaled M. Ziada, MD Director, Cardiovascular Catheterization Laboratories Gill Heart Institute, University of Kentucky UK/AHA Strive to Revive Symposium May 2013

More information

Canadian Journal of Cardiology 27 (2011) 529 533. Editorial

Canadian Journal of Cardiology 27 (2011) 529 533. Editorial Canadian Journal of Cardiology 27 (2011) 529 533 Editorial From Primary to Secondary Percutaneous Coronary Intervention: The Emerging Concept of Early Mechanical Reperfusion With Delayed Facilitated Stenting

More information

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada, Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting

More information

Cardiac Rehabilitation: Strategies Approaching 2020

Cardiac Rehabilitation: Strategies Approaching 2020 ACC Banff 2015 Cardiac Rehabilitation: Strategies Approaching 2020 James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Libin Cardiovascular

More information

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Stent for Life Initiative How can we improve system delay and patients delay in STEMI Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration

More information

ST Segment Elevation Nothing is ever as hard (or easy) as it looks

ST Segment Elevation Nothing is ever as hard (or easy) as it looks ST Segment Elevation Nothing is ever as hard (or easy) as it looks Cameron Guild, MD Division of Cardiology University of Mississippi Medical Center February 17, 2012 Objectives 1. Describe the electrical

More information

«Catch me if you can» A s3cky thrombus problem. Dr F. De Vroey (JEUNE ) Grand Hôpital De Charleroi Belgique

«Catch me if you can» A s3cky thrombus problem. Dr F. De Vroey (JEUNE ) Grand Hôpital De Charleroi Belgique «Catch me if you can» A s3cky thrombus problem Dr F. De Vroey (JEUNE ) Grand Hôpital De Charleroi Belgique Clinical case 39- y- old female, ac3ve smoker Presented with 48 hours of inconstant chest pain

More information

Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial

Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich

More information

Provider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469)

Provider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469) Provider Checklist-Outpatient Imaging Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code 78451-78454 78469) Medical Review Note: Per InterQual, if any of the following are present,

More information

Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith

Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith Māori Pathways to and Through Health Care for STEMIs in New Zealand Summer Studentship Research by Ellie Tuzzolino- Smith Terminology & Current Practice STEMI: S-T elevation Myocardial Infarction. Determined

More information

or can your blood ever really be too thin? Jason Haag

or can your blood ever really be too thin? Jason Haag Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8 th Edition) i Anticoagulation in Coronary Artery disease: or can your blood

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest

More information

Diagnostic and Therapeutic Procedures

Diagnostic and Therapeutic Procedures Diagnostic and Therapeutic Procedures Diagnostic and therapeutic cardiovascular s are central to the evaluation and management of patients with cardiovascular disease. Consistent with the other sections,

More information

OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS

OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS Division of Cardiology, Mount Sinai Hospital, New York, NY, USA Yuliya Vengrenyuk, PhD; and Annapoorna Kini, MD OCT ASSESSMENT OF CUTTING

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

The Bioresorbable Vascular Stent Dr Albert Ko

The Bioresorbable Vascular Stent Dr Albert Ko The Bioresorbable Vascular Stent Dr Albert Ko Dr Albert Ko MB BS, FRACP, FCSANZ Interventional/General Cardiologist Ascot Cardiology Symposium 2013 Treatment Goals for Coronary Artery Disease Relieve of

More information

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Acute Coronary Syndromes: oral antithrombotic therapy Focus on

More information

Remote Delivery of Cardiac Rehabilitation

Remote Delivery of Cardiac Rehabilitation Remote Delivery of Cardiac Rehabilitation Bonnie Wakefield, RN, PhD Kariann Drwal, MS Melody Scherubel, RN Thomas Klobucar, PhD Skyler Johnson, MS Peter Kaboli, MD, MS VA Rural Health Resource Center Central

More information

Mission: Lifeline EMS Recognition Guide

Mission: Lifeline EMS Recognition Guide Mission: Lifeline EMS Recognition Guide This Mission: Lifeline EMS Recognition Guide was developed to provide information about Mission: Lifeline EMS Recognition processes and criteria. If you have any

More information

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris

How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore

More information

DATE: 29 August 2012 CONTEXT AND POLICY ISSUES

DATE: 29 August 2012 CONTEXT AND POLICY ISSUES TITLE: Dual Antiplatelet Therapy and Enoxaparin or Unfractionated Heparin for patients with ST-elevation Myocardial Infarction: A Review of the Clinical Evidence DATE: 29 August 2012 CONTEXT AND POLICY

More information

ESC PCI Guidelines: / Sigmund Silber et al. 1

ESC PCI Guidelines: / Sigmund Silber et al. 1 For the first time! ESC PCI Guidelines: / Sigmund Silber et al. 1 in 2002: 649.332 in 2002: 541.964 ESC PCI Guidelines: Introduction and Definitions / Sigmund Silber et al. 2 ESC PCI Guidelines: Introduction

More information

Non-invasive FFR Using Coronary CT Angiography and Computational Fluid Dynamics Predicts the Hemodynamic Significance of Coronary Lesions

Non-invasive FFR Using Coronary CT Angiography and Computational Fluid Dynamics Predicts the Hemodynamic Significance of Coronary Lesions Non-invasive FFR Using Coronary CT Angiography and Computational Fluid Dynamics Predicts the Hemodynamic Significance of Coronary Lesions Andrejs Erglis, Sanda Jegere, Zanda Runkule, Ligita Zvaigzne, Dace

More information

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die

More information

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,

More information

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015 Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet

More information

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University

More information

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial)

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) Katrin A. Fiedler, Michael Maeng, Julinda Mehilli, Stefanie Schulz, Robert

More information

Editorial. Adult Cardiology - Meta-analysis

Editorial. Adult Cardiology - Meta-analysis Editorial Adult Cardiology - Meta-analysis Simple Versus Complex Bifurcation Stenting Strategies A Meta Analysis of Randomized Controlled Trials in the Drug Eluting Stent Era Ana Beatriz R. Medrano, MD

More information

Review Article A review on percutaneous coronary intervention vs. coronary artery bypass graft surgery.

Review Article A review on percutaneous coronary intervention vs. coronary artery bypass graft surgery. Kathmandu University Medical Journal (2003) Vol. 1, No. 4, Issue 4, 284-287 Review Article A review on percutaneous coronary intervention vs. coronary artery bypass graft surgery. Karki DB 1 Neopane A

More information

ACTION Registry - GWTG: Defect Free Care for Acute Myocardial Infarction Specifications and Testing Overview

ACTION Registry - GWTG: Defect Free Care for Acute Myocardial Infarction Specifications and Testing Overview Measure Purpose Numerator To provide defect free AMI care to all patients. Meaning all of the ACC/AHA endorsed performance measures are followed for eligible patients. Count of Care patients that received

More information

Philippine Heart Association Acute Coronary Syndrome Registry (PHA ACSR) Updates 5/31/2013 Edsa Shangrila. PHA 44 th Annual Convention

Philippine Heart Association Acute Coronary Syndrome Registry (PHA ACSR) Updates 5/31/2013 Edsa Shangrila. PHA 44 th Annual Convention Philippine Heart Association Acute Coronary Syndrome Registry (PHA ACSR) Updates 5/31/2013 Edsa Shangrila PHA 44 th Annual Convention Importance of doing a registry Measures healthcare delivery (trends

More information

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Time to Treatment is critical for STEMI patients For patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary

More information

PCI vs. CABG for Left Main Disease

PCI vs. CABG for Left Main Disease The EXCEL Ti Trial Design, Status, t and Timelines Gregg W. Stone, MD Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation PCI vs. CABG for Left Main Disease

More information

For the NXT Investigators

For the NXT Investigators Diagnostic performance of non-invasive fractional flow reserve derived from coronary CT angiography in suspected coronary artery disease: The NXT trial Bjarne L. Nørgaard, Jonathon Leipsic, Sara Gaur,

More information

Conflict of Interest Disclosure

Conflict of Interest Disclosure Conflict of Interest Disclosure Abiomed Personal: None Sponsor of PROTECT-II trial and EBC travel Pathophysiology When a critical mass of LV is necrotic and fails to pump, stoke volume and CO falls Myocardial

More information

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention J_ID: Z7V Customer A_ID: 2011_PCI_Guideline Cadmus Art: CCD23390 Date: 3-November-11 Stage: Page: 1 ID: kandasamy.d I Black Lining: [ON] I Time: 12:16 I Path: N:/3b2/CCD#/Vol00000/110478/APPFile/JW-CCD#110478

More information

GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES -

GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES - EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.1 Appendix 1 December 2008 GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA

More information

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,

More information

Stenting in Acute Myocardial Infarction

Stenting in Acute Myocardial Infarction Home SVCC Area: English - Español - Português Stenting in Acute Myocardial Infarction David Antoniucci, MD; Renato Valenti, MD Division of Cardiology and Interventional Cardiovascular Catheterization Laboratory,

More information

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know Acute Coronary Syndrome What Every Healthcare Professional Needs To Know Background of ACS Acute Coronary Syndrome (ACS) is an umbrella term used to cover a spectrum of clinical conditions that are caused

More information

Improving PCI Benchmark times in a Non-PCI World

Improving PCI Benchmark times in a Non-PCI World Improving PCI Benchmark times in a Non-PCI World May 2011 St David s Georgetown Hospital, Georgetown Texas Margaret Connors BSN, RN, CEN Kirk Sinclair BSN, RN, CEN National Processes/ Mission LifeLine

More information

Same-Day PCI: Guidelines & Best Practices for In-N-Out Procedures

Same-Day PCI: Guidelines & Best Practices for In-N-Out Procedures Same-Day PCI: Guidelines & Best Practices for In-N-Out Procedures Michael Guiry, PA-C, MBA AVP, Cardiovascular Services North Shore LIJ Health System New York I, Michael Guiry, DO NOT have a financial

More information

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of

More information

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION

More information

on behalf of the AUGMENT-HF Investigators

on behalf of the AUGMENT-HF Investigators One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas

More information

Automatic External Defibrillators

Automatic External Defibrillators Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Cardiac Rehab. Home. www.homecareforyou.com. Do you suffer from a cardiac condition that is limiting your independence in household mobility?

Cardiac Rehab. Home. www.homecareforyou.com. Do you suffer from a cardiac condition that is limiting your independence in household mobility? TM Nightingale Home Cardiac Rehab Do you suffer from a cardiac condition that is limiting your independence in household mobility? Such as, 1. A recent heart attack 2. A heart condition coronary artery

More information

OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON

OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON - Baseline preliminary results - Takashi Akasaka, MD, PhD, FESC Wakayama Medical University,

More information

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Recommendations of the European Society of Cardiology Updated version December 2002 Task Force on management

More information